Web15. feb 2024 · PHERGain-2 study is an additional step forward and aims to assess the feasibility of chemotherapy de-escalation with neoadjuvant HP followed by adjuvant HP or T-DM1 using a pathological response-adapted strategy in low-risk HER2-positive early breast cancer pts. Trial Design: PHERGain-2 is a multicenter, open-label, non-comparative, phase … WebVerbesserung der Behandlungsergebnisse chronischer Schmerzerkrankungen des Bewegungssystems durch den Einsatz krankheitsübergreifender Multilevel-Diagnostik und …
ESMO Breast Cancer Congress OncologyPRO
WebTrastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study. Authors : Pérez-García JM, Gebhart G, Borrego MR, Schmid P, Marmé F, Prat A, Dalenc F, Kerrou K, Colleoni M, Braga S, Malfettone A, Sampayo-Cordero M, Cortés J, Llombart-Cussac A Year : 2024 Journal : Future Oncol Web1. jún 2024 · In the European phase II PHERGain study reported in The Lancet Oncology, Pérez-García et al found that an F-18 fluorodeoxyglucose positron-emission tomography … home town song
Cancers Free Full-Text Cardiotoxicity, Cardioprotection, and ...
WebThe definitive assessment of pathological complete response was done at this primary analysis; follow-up to assess invasive disease-free survival is continuing, hence these … WebThe aim of CompassHER2-pCR study is to evaluate the de-escalation of chemotherapy for HER2 positive breast cancer after neoadjuvant chemotherapy and targeted therapy. 4 The PHERGain study will assess the effects of neoadjuvant treatment with dual target therapy (± endocrine therapy according to hormone receptor status) in patients with HER2 … Web26. máj 2024 · The PHERGain study was carried out in this medical-scientific context. This phase II clinical trial involved researchers from 45 centres in seven European countries, … hisonic 120b